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Intercellular communication in many organs is maintained via intercellular gap junction channels composed of connexins, a large protein
family with a number of isoforms. This gap junction intercellular communication (GJIC) allows the propagation of action potentials (e.g., in brain,
heart), and the transfer of small molecules which may regulate cell growth, differentiation and function. The latter has been shown to be involved
in cancer growth: reduced GJIC often is associated with increased tumor growth or with de-differentiation processes. Disturbances of GJIC in the
heart can cause arrhythmia, while in brain electrical activity during seizures seems to be propagated via gap junction channels. Many diseases or
pathophysiological conditions seem to be associated with alterations of gap junction protein expression. Thus, depending on the target disease
opening or closure of gap junctions may be of interest, or alteration of connexin expression. GJIC can be affected acutely by changing gap
junction conductance or – more chronic – by altering connexin expression and membrane localisation. This review gives an overview on drugs
affecting GJIC.
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Pharmacology is the science of the interaction of substances,
usually called drugs, with living organisms. The clinical aspect
of this science is the use of a certain interaction to influence the0005-2736/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2005.09.007
* Corresponding author.
E-mail address: aida.salameh@medizin.uni-leipzig.de (A. Salameh).pathophysiology of a disease. A drug is any chemical agent
affecting processes of living. This broad definition includes an
extensive number of agents and mechanisms of action. A
certain aspect is that – to speak with Paracelsus – ‘‘every agent
is a poison, nothing is without poison and it is solely the dose
which makes that an agent is not a poison’’. That means – and
this will be important for the issue of pharmacology of gap
junctions – that a drug may have beneficial effects at low doses
and may be deleterious at higher doses. This might be ofta 1719 (2005) 36 – 58
http://www
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affected.
While the classical pharmacological approach was starting
at the traditional evidence from older times that a certain
medicine has been used for treatment of a disease with
subsequent purification of the active agent and characterization
of the mechanism of action, modern pharmacology starts with
the definition of a drug target, i.e., a structure, mostly a protein,
which is believed to play a key role in the pathophysiology of a
disease. Subsequently, an innumerate amount of agents is
tested by screening assays for its efficacy at the target structure
(often using binding assays), followed by a test of the effective
agents in certain cell culture or organ models, to define whether
they have agonist or antagonistic affects, how they affect the
physiology of the organ and whether they might influence the
pathomechanism of the disease.
In the last years it has become clear that cells forming an
organ communicate with each other and that this intercellular
communication is a basic prerequisite for proper organ
function. Previously, communication was known via nerves,
via hormones and mediators. Here we are facing another type
of communication, the direct cell-to-cell communication via
gap junctions (gap junction intercellular communication;
GJIC), realized via intercellular gap junction channels, formed
by two hemichannels provided by either of the two neighboring
cells. Each hemichannel, or connexon, is a hexameric pore
structure made from 6 protein subunits, the connexins. At
present, the connexins (Cx) comprise a gene family of 20
members in mouse and 21 in human [1] (hCx23, hCx25,
hCx26, hCx30.2, hCx30, hCx31.9, hCx30.3, hCx31, hCx31.1,
hCx32, hCx36, hCx37, hCx40.1, hCx40, hCx43, hCx45,
hCx46, hCx47, hCx50, hCx59, hCx62; h=human, Cx=con-
nexin, the number gives the approximate molecular weight in
kDa). The various connexin isoforms differ with regard to their
molecular weight due to different lengths of their C-terminals.
A connexin is a protein with 4 transmembrane spanning
domains, two extracellular and 1 intracellular loop, and with N-
and C-terminal at the intracellular side [2]. Gap junction
channels allow the propagation of an electrical impulse (action
potential) and the transfer of small molecules (up to 1000
Dalton). Connexins are synthetised in the rough endoplasmic
reticulum, folded and inserted into vesicles for transfer to the
Golgi apparatus, where they are oligomerized to hexameric
hemichannels. Thereafter, they are transported along micotub-
ular structures to the plasma membrane and dock to another
hemichannel of the neighboring cell thus forming a complete
gap junction channel (see [3–5]. This process includes
interaction with the cytoskeletal apparatus, in particular with
zonula occludens protein 1 ZO-1 (for review, see [6]).
Connexins are degraded with short half-life times (see above)
via either the lysosomal or (predominantly) the proteasomal
pathway.
Intercellular coupling can be regulated by either the number
of channels as well as by the mean open time, the mean closed
time, and the single channel conductance. The number of
channels is either controlled by the rate of synthesis of
connexins, their transport from the sarcoplasmic reticulum tothe trans-Golgi network [3] and their integration and assembly
in the membrane [7], or by their degradation [8]. The half life
time of these channels is with 1–5 h rather short [9,10] (Cx43:
about 90 min; Cx45 about 2.9 h: [11]). Function and life-time
of connexins including connexin trafficking, assembly, disas-
sembly, degradation and control of gating are controlled – at
least partially – by phosphorylation [12].
2. General approaches
Pharmacology of GJIC is still at its beginnings and we need
to define agents affecting GJIC for a subsequent test of these
agents in various models of disease. In the following
paragraphs we summarize the classes of agents and the types
of action which have been shown to affect GJIC. We will first
describe mechanisms and drugs acting on gap junction
conductance rather than on number of channels, section 1
describing those drugs which reduce coupling, section 2 those
enhancing coupling. This will be followed by a third section on
drugs and mechanisms known to act on the number of channels
by acting on expression, synthesis, trafficking, docking or
degradation. Finally we will focus on possible new perspec-
tives for the treatment of diseases (Fig. 1).
Before starting with these a small excurse on ionic
mechanisms should be given which is necessary for the
understanding:
2.1. Ions
There is no certain class of drugs affecting gap junctions. In
contrast, many agents can affect the channels: Thus, increasing
concentrations of ions such as Na+, Ca++, Mg++, and H+ can
reduce acutely gap junction conductance within minutes [13–
15]. Regarding Ca++, reduction in gj occurs if the intracellular
calcium concentration exceeds the range 320–560 nmol/l [16].
Intracellular acidification is known to decrease junctional
electrical coupling in cardiomyocytes and in Purkinje fibres
[14,17,18]. Regarding the pH sensor, the carboxy tail length
has been demonstrated as a determinant of the pH sensitivity
[19]. Further investigations [20] revealed a new model of
intramolecular interactions in which the carboxy terminal
serves as an independent domain which can bind to another
separate domain of the connexin protein (e.g., a region
including His-95) closing the channel, comparable to the
ball-and-chain-model for potassium channels. Cx40 and Cx43
seem to act synergistically and enhance pH sensitivity when
coexpressed [21]. Na+-withdrawal in adult rat cardiomyocytes
induced electrical uncoupling within 3 min which has been
considered a consequence of impaired Na+/Ca++-exchange
[16]. On the other hand, increases in [Na+]i can cause
uncoupling within 500 ms in Purkinje fibers [22] which – on
the other hand – might be secondary to a rise in intracellular
Ca++ via the Na+/Ca++-exchange mechanism. Besides this,
Ca++ is known to interact with calmodulin. Calmodulin,
however, can interact with connexins and plays a role in
chemical channel gating [23,24]. According to these studies,
voltage-sensitivity and CO2-asensitivity of Cx45 as well as
Fig. 1. Schematic view of a gap junction channel and its constituent component, the connexin, as a target of pharmacology.
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issue and possible interaction between H+ and Ca++ ions are
extensively discussed and reviewed recently by Peracchia [25].
Elevation in [Mg++]i from 1 to 10 mmol/l at pH=7.4 in the
absence of calcium has also been reported to reduce junctional
conductance in pairs of adult guinea pig cardiomyocytes [14].
A Hill coefficient of 3.0 was calculated. Since the slope of the
pCa-gj and the pMg-gj relationships were similar, it was
suggested that both divalent cations bind to the same receptor
site.
2.2. Drugs used for acute closure of gap junctions (Table 1)
Drugs may affect intracellular ionic homeostasis thereby
indirectly altering gap junction conductance. Thus, cardiac
glycosides bind to and inhibit the membrane Na/K-ATPase
leading to alteration of Na+/Ca++ exchange finally enhancing
intracellular concentrations of Na+ and Ca++ which inconsequence can uncouple the cells [26]. This uncoupling
occurs at nearly therapeutic concentrations of, e.g., 0.68 AM
ouabain [22] and, thus, may contribute to the well-known
arrhythmogeneity of digitalis. Following this acute uncoupling,
later ouabain (in extremely high concentrations of 1 mM) leads
to decreased trafficking of connexins with reductions in Cx40
and Cx43 expression [27]. However, it should be noted that the
latter action is only of academic interest, since ouabain
concentrations of 1 mM are far out of the therapeutic
concentration rang (which is in the order of 0.1–0.5 AM)
(Table 1).
Regarding the effects of amines, such as histamine,
adrenaline and noradrenaline, there are mainly investigations
on the coupling-increasing effects of stimulation of cAMP-
pathway which typically is activated via h-adrenoceptors [28];
for review, see [29]; and see next section on coupling agents).
The role of a-adrenoceptors in regulation of cardiac or vascular
gap junction conductance remains unclear. However, in acinar
Table 1
Agents acutely uncoupling cardiovascular gap junctions
Class Agents Proposed mechanism Reported Cx Ref.
Ions Na+, Ca++, Mg++ direct effects? 43 [13–15]
Ca++ Via calmodulin? 45, 32 [23,24]
H+ Ball and chain 40, 43, 32 [17–21]
Drugs/mediators Cardiac glycosides, ouabain Elevation of [Ca++]i 43 [22,26]
a-adrenoceptor stimul.
(phenylephrine)
PKC 32?, 43 [30,31]
Histamine H1-receptor/PKC 43 [32]
IGF-1 PKCg, disassembly of g j 43 [44]
PDGF PKC 43 [53]
Angiotensin-II AT1-receptor/PKC? 43 [63–66]
VEGF Type2-VEGF-receptor 43 [67,68]
Tyrosine kinase /ERK
Thrombin, endothelin, AlF4
 Src-tyrosine kinase 43 [69]
Lysophosphatidic acid Src-tyrosine kinase 43 [69]
Carbachol Ser368-phosphorylation,
cGMP/PKG
43 [48,71]
Acetylcholine Nitric oxide 32, 26 [73]
Cholecystokinin-octapeptide ? 32, 26 [74]
IL-1h ? 32, 43 [75,76]
Polyamines: spermine, spermidine ? 40 [79]
Nitric oxide ? 37 [80]
Quinine, mefloquine ? 36, 45, 50 [84,85]
Ilmaquinone ? 43 [51,87]
(26, 31, 32)a
Dicoumarol Reduced phosphorylation 43 [89]
Fenamates: meclofenamic acid,
niflumic acid, flufenamic acid
? 43 [91–93]
FGF-2 PKC( 43 [42]
Dephosphorylating agents 2,3 butandione monoxime Unknown mechanism 43 [36]
Phorbol esters 12-O-tetradecanoyphorbol-13-acetate Activation of PKCb/Ca++? 26, 31, 32, [50,51,59]
(TPA) 36, 43
PKC inhibitors Staurosporine Inhibition of PKCb 43 [62]
Lipophilic agents and fatty acids Heptanol, octanol Incorporation? 43 [43,105–107,113–115]
Arachidonic acid, oleic acid,
palmitoleic acid, decaenoic
Acid, myristoleic acid
PKC (oleic acid)
Reduced open
Probability (heptanol)
43 [108,109]
Glycyrrhizic acid metabolites 18-a-glycyrrhetinic acid Phosphorylation?
18-h-glycyrrhetinic acid Aggregation of Cx-subunits?
Carbenoxolone
Narcotics Halothane, ethrane, isoflurane Incorporation? 43, 40 [103]
Reduced meanopen time
Metabolites ATP-decrease Dephosphorylation 43 [36,39,49]
Diacylglycerol/
1-oleoyl-2-acetyl-sn-glycerol
Unknown mechanism/disturbance
of the lipid bilayer?
43
Eicosanoids 11,12-epoxyeicosatrienoic acid
(late effect) thromboxane A2
ERK1/2
Cx43 internalization
(37, 40, 43)?
43
[116]
[117]
IP3-receptor blocker 2-aminoethoxydiphenyl borate Unknown mechanism 43? [94]
Cannabinoids D9-tetrahydrocannabinol ERK1/2 43 [118]
‘‘(37, 40, 43)?’’ means that experiments have been carried out in endothelial cells which are known to express Cx37, Cx40 and Cx43, but that it has not been clarified
which of these Cx is involved.
a Only moderate response [51].
b Probably depending on the isoform of PKC.
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mol/l adrenaline elicits a reduction in dye coupling [30], which
could not be mimicked with isoprenaline, but could be
antagonized by phenoxybenzamine. Thus, the uncoupling
effect of adrenaline in this tissue is mediated by stimulation
of the a-adrenoceptor. In several tissues, a-adrenergic stimu-
lation leads to uncoupling. Similarly, a-adrenergic stimulation
with phenylephrine in adult rat ventricular cardiomyocytes
acutely decreases gap junction coupling in a PKC-dependentmanner [31]. Histamine, acting on H1-receptors, which also are
Gq/11 coupled, leads to uncoupling and reduced membranous
Cx43 obviously involving PKC [32] (H2 effect, see next
section) (Table 2).
This leads to the fact that gap junction conductance can be
regulated by phosphorylation of the C-term which comprises
consensus sites for several kinases such as cAMP-activated PK
(PKA), protein kinase C (PKC; cave: various isoforms), PKG,
p34cdc2, casein kinase 1, mitogen-activated protein (MAP)
Table 2
Agents reported to acutely enhance gap junctional intercellular communication
Class Agents Proposed mechanism Reported Cx Ref.
cAMP-enhancing drugs cAMP, forskolin, isoprenaline PKA 40, 45 [55,119–122]
Antiarrhythmic drugs Tedisamil PKA ? [98]
Antiarrhythmic peptides AAPnat, AAP10, cAAP10RG, PKCa 43 [41,128,131–136,132–139]
HPP-5, ZP123 PKC? 43
Eicosanoids 11,12-epoxyeicosatrienoic acid
(early effect)
PKA (37, 40, 43)? [116]
Phorbol ester TPA PKCa 43 [47,48]
Unsaturated fatty acids Eicosapentaenoic acid inhibition of hypoxia-induced
tyrosine-kinase-activation
(37, 40, 43)? [140,141]
Receptor ligands 5-hydroxytryptamine ? 40, 43 [144]
Histamine H2-receptor, PKA 43 [32]
TPA=12-O-tetradecanoylphorbol 13-acetate; HPP-5=N-3-(4-hydroxyphenyl)-propionyl-Pro-Hyp-Gly-Ala-Gly. ‘‘(37, 40, 43)?’’ means that experiments have been
carried out in endothelial cells which are known to express Cx37, Cx40 and Cx43, but that it has not been clarified which of these Cx is involved.
a Probably depending on the isoform of PKC.
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oncogene v-src (pp60Src) have been shown to target connexins
(for review, see [33,34]). Phosphatases or conditions like
ischemia can lead to de-phosphorylation of connexins (for
review, see [35]). Thus, the dephosphorylating agent 2,3
butandione monoxime (BDM) reduces GJIC [36]. However,
this was not correlated with a change in the ratio between non-
phosphorylated and phosphorylated Cx43, so that the authors
concluded, that the BDM effect might be mediated via
regulatory proteins associated with Cx43. Dephosphorylation
by endogenous protein phosphatases leads to a run down in
channel conductance which can be antagonized by phosphatase
inhibitors such as okadaic acid [37]. Dephosphorylation of
Cx43 in heart has been suggested to be mediated via PP1-like
phosphatases [38]. Similarly, loss of [ATP]i has been reported
to result in gap junction uncoupling, so that the spontaneous
rundown of gap junction current in double cell patch clamp
experiments can be counteracted by addition of ATP to the
pipette solution [39]. This mechanism may be involved in
cellular uncoupling in the course of cardiac ischemia and thus
might contribute to arrhythmogenesis in cardiac ischemia [36].
Ischemia leads to de-phosphorylation of Cx43 which can be
blocked by phosphatase inhibitors such as ocadaic acid (all
phosphatases) or caliculin (inhibits PP1 and PP4) [38].
Interestingly, ischemic preconditioning leads to PKC-activa-
tion, enhanced Cx43 phosphorylation and reduced myocardial
damage [40].
Different isoforms of a protein kinase may lead to different
responses as has been shown for PKC: while PKCa can
phosphorylate Cx43 and enhance GJIC [41], PKC( reduces
GJIC (acute effect of FGF-2 exposition) [42]. PKC activation,
e.g., by oleic acid was shown to result in gap junction
disassembly and Cx43 Ser368 phosphorylation. While this
action could be blocked by classical PKC inhibitors, it was
not sensitive to specific PKCa-inhibition by Go¨6976 [43]. In
rabbit lens cells, IGF-1 induced PKCg-activation leads to
Cx43 phosphorylation and decrease in Cx43 and gap junction
plaques [44]. PKCg translocates to caveolin-1 lipid rafts to
which Cx43 is associated [45]. In human lens cells, Cx43 also
is phosphorylated by PKCg causing disassembly and loss of
Cx43 from the membrane, while PKCa increased Cx43 in themembrane [46]. Much has been written about the effects of
PKC or PKA activation (for recent review, see [29]);
however, the results are still conflicting: PKC can be directly
activated with phorbol esters such as 12-O-tetradecanoyphor-
bol-13-acetate (TPA) in comparison to the inactive phorbol
ester 4a-phorbol-12,13-didecanoate (aPDD). Activation of
PKC by these agents was described in some studies to
enhance macroscopic gap junction conductance [47,48], while
in others there was no effect [49]. In cardiac myocytes,
increase as well as decrease in gj has been observed in pairs
of neonatal cardiomyocytes after PKC-activation by TPA
[47,50]. In a systematic study, the effect of TPA on various
connexins has been evaluated. According to this study TPA (2
h) reduces GJIC in transfected HeLa-cells coupled by Cx26,
Cx31, Cx32, Cx36 and Cx43, but not in cells coupled by
Cx45 or Cx56 [51]. In liver cells, TPA-dependent PKC
activation also involving ERK1/2 leads to reduced GJIC and
enhanced Cx43 degradation [52]. Burt and Steele [53]
showed that cells coupled via Cx40 were not uncoupled by
PDGF in contrast to Cx43-coupled cells, which could be
uncoupled by PDGF acting via PKC-dependent Ser368
phosphorylation. Thus, the phorbolester effect depends on
the connexin involved and on the other hand on the PKC
isoform.
In cardiac tissue several isoforms of PKC are expressed
including PKCa, PKCh, PKC(, PKCs and PKCg (rabbit
heart; [54]). TPA treatment is assumed to result in a rapid
translocation of PKCa and PKC( in cultured neonatal rat
cardiac myocytes [55]. Thus, one may argue that not all
isoforms contribute to the gap junction regulation and
differences between various preparations or tissues may
depend on the subtypes of PKC involved. In addition, Kwak
et al. [56] found that TPA increases electrical conductance but
decreases permeability as assessed by dye coupling in
neonatal rat cardiomyocyte gap junction channels. TPA
activates both PKCa and PKC( isoforms (which seem to
exert opposite effects on g j) which might explain the
diverging results by a different PKAa/PKC( activation ratio.
Both PKCa and PKC( have been shown to phosphorylate
Cx43, however, only PKC( phosphorylates directly [57]
(Table 3).
Table 3
Agents affecting expression, synthesis, assembly, docking and degradation of gap junctions
Class Agents Proposed mechanism Reported
Cx
Ref.
Carotenoids All-trans retinoic acid Posttranslational regulation? 43 [150]
Lycopene Enhanced Cx-expression 43 [151]
TAC-101 Agonism at retinoic acid receptors 43 [152]
Indolo[3,2-b]carbazole Reduced Cx-expression 32 [155]
Hormones Estradiol (17h-estradiol) Enhanced Cx-expression (normal endometrium) 26 [172]
ERa, reduced Cx-expression (cancer cells) 26, 32 [157]
Reduced SE368-phosphoryl. 43 [173]
Enhanced (vascular) expression 43 [174]
FSH Enhanced Cx-expression 43 [175]
LH PKA, MAPK, reduced Cx-expression 43 [175]
Thyroid hormone (T3) Enhanced Cx-expression 43 [176,177]
Miscellaneous Kaempferol Enhanced phosphorylation and expression 43 [146]
h-sitosterol Enhanced expression 43 [147]
Anisomycin p38-MAPK-activation/reduced Cx32 expression 32 [161]
Cholesterol Reduced endothelial Cx-expression 37, 40 [179]
Enhanced neointimal Cx-expression 43 [178]
LPS Reduced Cx-expression 43 [200]
Enhanced Cx-expression 43 [201]
Balifomycin A Enhanced Cx-presence by inhibition of lysosomes 43 [222]
ALLN, lactacystin, clastolactacystin,
and epoxomicin
Enhanced Cx-presence by inhibition of proteasomes 43 [222]
Ethanol Reduced Cx-synthesis 43 [196]
Brefeldin A Inhibits Cx-transport in the Golgi apparatus 43 [4]
Monensin Trapping of Cx in the trans-Golgi network 43 [212]
Cancerogens Wy-14,643, methapyrilene, hexachlorobenzene,
2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD),
chloroform, p-dichlorobenzene
Reduced Cx-expression 32 [158]
Drugs, mediators Nicotine nACh-receptor-agonist, reduced Cx-expression 43 [181]
HMG-CoA-reductase inhibitors (statins) Enhanced Cx-expression (endothelial cells) 43 [181]
Reduced Cx-expression (atheroma vascular cells) 43 [180]
Enhanced Cx-expression (endothelial cells) 37 [179]
Bicuculline methiodide GABA(A)-receptor antagonist 32, 43 [164]
Enhanced Cx-expression
Chloroquine, primaquine Enhanced Cx-presence by inhibition of lysosomes 43 [222]
TNFa Reduced Cx-expression 37, 40 [208]
Enhanced Cx-expression, via p38MAPK (cardiac cells) 43 [203,204,207]
Reduced promoter activity (HeLa cells) 43 [200]
Endothelin ETA-receptor, ERK1/2, enhanced Cx expression 43 [194]
Angiotensin AT1-receptor, ERK1/2, p38 Enhanced Cx-expression 43 [194]
VEGF Enhanced Cx-expression via TGF-h 43 [68]
bFGF Enhanced Cx-expression 43 [198]
Epidermal growth factor EGF MEK/reduced Cx-expression 43 [166]
Cx-internalization 43 [167,168]
Second messenger cAMP, 8-Br-cAMP PKA; induction of expression 43, 45 [190]
AC activator Forskolin cAMP/PKA, induction of expression 43 [191–193]
Extracellular loop
peptides
GAP27, GAP26 Inhibition of docking 37, 43 [216,217]
E1 and E2 peptides Inhibition of docking 32, 43 [214,215]
P180–195/Cx43 Inhibition of docking 43 [219]
P177–192/Cx40 Inhibition of docking 40 [219]
Antisense GTCACCCATGTCTGGGCA Inhibition of Cx expression 43 [189]
Oligonucleotides GTCACCCATCTTGCCAAG Inhibition of Cx expression 40 [189]
AC=adenylylcyclase; ALLN=acetyl-leucyl-leucyl-norleucinal; bFGF=basic fibroblast growth factor; FSH=follicle stimulating hormone; LH=luteinizing
hormone; LPS=lipopolysaccharides; VEGF=vascular endothelial growth factor.
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co-workers [48] used SKHep1 cells which normally express
low levels of Cx45 and are not capable of Lucifer Yellow dye
transfer, and transfected these cells with Cx43. The absence of
dye transfer in cells only expressing Cx45 was not influenced
by 8-Br-cAMP (PKA-activation), TPA (PKC activation) or 8-
Br-cGMP (PKG activation). On the other hand, PKC activation
by TPA favored the smaller conductance state of Cx43channels (61 pS events), along with a decrease of the relative
frequency in 89 pS events. This complicated behavior may
eventually account for the diversity of results being reported in
the literature. In parental non-transfected SKHep1 cells which
were coupled via Cx45, activation of PKC induced an
additional 16 pS conductance state (together with the 22 and
36 pS conductances observed before). However, according to
Christ and Brink [58], the portion of a certain substate
A. Salameh, S. Dhein / Biochimica et Biophysica Acta 1719 (2005) 36–5842contributing to the macroscopic conductance is also necessary
to be considered. More recently, TPA was shown to reduce
coupling in HeLa–Cx43 cells and in HeLa cells expressing
both Cx43 and Cx45, but not in HeLa–Cx45 cells [59].
However, in another study HeLa cells transfected with Cx45
PKC activation increased gap junctional coupling [60]. These
contradictory results may be explained by the fact that Van
Veen and colleagues [60] used another phorbol ester (4-a-
phorbol 12-myristate 13 acetate; PMA). Thus, it might be
speculated that different PKC isoforms might have been
activated. Regarding the role of cGMP, Ngezahayo and
coworkers presented evidence that in GFSHR-17 granulosa
cells intracellular cGMP might cause Ca++ entry, K+-efflux
accompanied by cell shrinkage and gap junction uncoupling, a
process which might play a role in apoptotic/necrotic processes
[61].
Interestingly, PKC inhibition using staurosporine (300
nM) lead to uncoupling in cultured neonatal rat cardiomo-
cytes, as demonstrated by Saez et al. [62]. This effect could
be reversed by TPA. Staurosporin in these experiments
reduced the incorporation of 32P into Cx43 supporting the
view that PKC-dependent phosphorylation of Cx43 enhances
intercellular coupling. From 2D-gel electrophoresis experi-
ments and analysis of the phosphorylation sites Saez and
colleagues [62] concluded that a protein kinase other than
PKC might phosphorylate Cx43 in vivo. Another factor
taken into account is the question whether Cx43 prior to
treatment with TPA is in the non-phosphorylated or in the
phosphorylated state. The authors concluded that Ser-368
and Ser-372 might be the targets of PKC phosphorylation in
those cells which show uncoupling effects of PKC
activation. However, it should be kept in mind that
staurosporine in not very specific for PKC.
Angiotensin has also been shown to influence gap
junction coupling in cardiac cells. The acute effects seem
to be mediated via AT1 receptors coupled to Gq/11 proteins
and protein kinase C. In adult ventricular cell pairs 1 Ag/ml
angiotensin-II rapidly decreased gj by 55% [63], which was
reversible within 3 min. Threshold concentration was 10
nmol/l. In subsequent experiments intracellular dialysis of 10
nmol/l angiotensin I resulted in a decrease of gj of 76%,
which was completely inhibited by intracellular dialysis of 1
nmol/l enalaprilat, demonstrating the possible existence of an
intracellular angiotensin converting enzyme [64]. Intracellu-
lar dialysis of angiotensin II also led to a decrease in gj. In
support of these findings renin, angiotensin I, angiotensin II
and angiotensin converting enzyme have been found in
cardiomyocytes using immunofluorescent staining [65]. The
existence of an intracellular angiotensin receptor is also
supported by a recent study [66]. Chronic exposure to
angiotensin-II can alter connexin expression (see next
section).
VEGF (=vascular endothelial growth factor), an angioge-
netic factor, acting on tyrosine kinase-coupled VEGF-receptors
(type 2) reversibly inhibits GJIC in endothelial cells within
15–30 min after application of 50 ng/ml VEGF with a
concomitant change in the phosphorylation of Cx43 [67].Besides this, a later upregulation of Cx43 (after 1 h) has been
observed [68].
Interestingly, in a Cx43 expressing cell line, Postma and co-
workers [69] described that lysophosphatidic acid, thrombin,
and endothelin induced uncoupling. This could be mimicked
by AlF4
, a direct activator of trimeric G-proteins, but was
insensitive to pertussis toxin, an inhibitor of Gi-proteins. In the
presence of the agonist, the coupling recovered within 1–2 h or
3–4 h (endothelin) due to receptor desensitization. The
uncoupling effect was independent from Ca++, PKC, MAPK,
membrane potential, Rho or Ras activation, but was sensitive to
tyrphostins and was not present in Src-deficient cells, so that
the authors concluded that Gq-coupled receptors may uncouple
Cx43-expressing cells via a Src-Tyr-kinase. Gi proteins
(typically associated with muscarinic receptors such as m2 or
m4) seem to regulate Cx43 trafficking and inhibition of Gi by
pertussis toxin inhibits gap junction plaque formation [70].
However, carbachol in human luteinizing granulose cells leads
to reduced GJIC via enhanced Cx43–Ser368 phosphorylation
[71], which might – from our point of view – be explained by
activation of other muscarinic receptors, such as m1, m3 or m5
which couple to Gq/11 (for review on muscarinic receptors:
[72]). In rat pancreatic acinar cells (which are coupled via Cx32
and Cx26) acetylcholine in high, supraphysiological concen-
trations (1–5 AM) can also reduce GJIC possibly via a nitric
oxide-dependent pathway [73]. In lower concentrations, it did
not affect GJIC. In the same cell type, it was shown that for
physiological concentrations of cholecystokinin-octapeptide
(CCK-OP) (1 nM) gap junction uncoupling follows secretion
[74].
Among the physiological mediators, cytokines such as
IL-1h lead to reduced GJIC via Cx43 in astrocytes [75] or
to a disappearance of Cx32 in rat liver cells [76]. Another
cytokine, TNFa, has been shown to reduce the phosphor-
ylated form of Cx43 in cornea fibroblasts thereby reducing
GJIC. Moreover, TNFa exposure (1000 U/ml; 2–24 h)
reduces GJIC and Ca++ wave propagation in brain endothe-
lial cells [77]. On the other hand, TNFa in combination
with interferon-g enhanced GJIC in cultured human mono-
cytes [78]. Regarding the effects of TNFa on Cx expression
see below (third section).
Endogenous polyamines are known to accumulate at the
end of the G1 phase of the cell cycle, have been suggested to
stabilize DNA and tRNA, and can block a number of ion
channels. Polyamines such as spermine (0.1–4.9 mM) or
spermidine (>5 mM) have been successfully used for
uncoupling of Cx40 channels in transfected N2A cells [79],
although it is not sure whether this has a physiological
function.
Nitric oxide is among the most important physiological
mediators in the vasculature but also in a number of other cells.
Normally the effects of NO rely on its ability to activate
soluable guanylate cyclase. Besides this, nitric oxide can
induce uncoupling in human umbilical vein endothelial cells
(HUVEC). This effect does not seem to be mediated via cGMP
[80]. It was also shown by this group that NO causes
uncoupling of Cx37 coupling but increases the formation of
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group demonstrated increases in Cx40 membrane incorporation
following application of the NO donor SNAP, which was
sensitive to PKA-inhibition with H89 [82]. Although it is
unclear at present how NO can activate PKA, these investiga-
tion shed light on the interesting fact that obviously NO can
modulate endothelial GJIC. Uncoupling of Cx43 coupled cells,
human uterine myocytes, has been previously shown by Roh
and coworkers [83].
Interestingly, effects of quinones and quinolines on GJIC
have also been described. The anti-malaria drug quinine, which
in plasmodium is supposed to inhibit heme polymerase, can
block Cx36 and Cx50 channel currents in transfected mam-
malian cells at 32 or 73 AM IC50, respectively, but does not
affect Cx26, Cx32, C40 or Cx43 channels, while Cx45
channels are moderately sensitive [84]. The underlying
mechanisms for these effects still remain unknown at present.
Mefloquine, an anti-malaria drug, blocks Cx36 channels (IC50:
300 nM) and Cx50 channels (IC50: 1.1 AM) while Cx43, Cx32
and Cx26 are less or not sensitive and can be blocked only with
very high concentrations [85]. Moreover, it can potentiate the
uncoupling effects of endothelin-1 or ATP in astrocytes [86].
Similarly, ilmaquinone reduces Cx43 phosphorylation (reduced
Cx43-P2 band) and GJIC [87]. Increased Cx43-Ser368
phosphorylation under quinines in rat liver cells seems to
involve EGF receptor activation and ERK1/2 [88]. According
to recent investigations, ilmaquinone predominantly uncouples
Cx43 channels within 15 min, but not Cx36, Cx45 or Cx57,
while Cx26, Cx31, Cx32 channels exhibit only moderate
responses [51].
In liver cell, a number of drug leading to gap junction
uncoupling has been identified. Thus, the vitamin K antagonist
dicoumarol (chemically a cumarine derivative; 3,3V-methylen-
bis(4-hydroxy-cumarine)) uncouples Cx43 coupled hepato-
cytes and reduces phosphorylated Cx43 with an IC50 of 3
AM, while warfarin, a related compound (however, a mono-
cumarine), is less effective (5–10 mM) [89]. Liver cell GJIC
also is reduced by vitamin K, menadione, a quinone, in
considerably high concentrations of 50–100 AM [90]. This
effect of vitamin K and dicoumarol may indicate that the
uncoupling action is not related to the vitamin K-like effect
but may be linked to its chemical structure (quinone-like
structures?).
A new group of drugs resulting in reversible gap junctional
uncoupling comprises the fenamates or anthranile acid deriva-
tives, which are part of the group of cyclooxygenase inhibiting
non-steroidal antiphlogistics, with an order of potency meclo-
fenamic acid>niflumic acid>flufenamic acid with IC50 values
of 25 to 40 AM [91]. The exact molecular mechanism of this
action demonstrated in SKHep1 cells expressing Cx43 remains
unclear, but is not related to cyclooxygenase inhibition, PKC
activation, intracellular pH, calcium or membrane depolariza-
tion. Arylaminobenzoates such as flufenamic acid can reduce
the open probability of gap junction channels formed by
various connexins in transected N2A cells [92]. Flufenamic
acid can also be used as a hemichannel blocker in bovine
corneal endothelial cells [93].Another reversible gap junction uncoupling agent is 2-
aminoethoxydiphenyl borate (normally used as IP3-receptor
blocker), which has been evaluated in normal rat kidney
fibroblasts leading to uncoupling with an IC50 of 5.7 AM [94].
However, the underlying mechanism of action is still
unknown.
Regarding toxic agents hexachlorobenzene, an epigenetic
carcinogen, reduces hepatic GJIC via reduced Cx32 and Cx26
expression [95]. Among liver toxic agents, Fe overload also
reduced GJIC in hepatocytes [96] as phenobarbital does [97].
Cisplatin, a cytostatic drug used in anticancer therapy,
causes G1 arrest of cell cycle together with premature cell
senescence and reduced GJIC in cultured human fibroblasts
[98].
Lindane (hexachlorocyclohexane, normally used as insecti-
zide) causes Ser368 phosphorylation of Cx43 and reduces
GJIC in liver ands also in myometrial cells [99]. This action
seems to involve oxidation of glutathione [100]. In addition, in
a Sertoli cell line a redistribution of Cx43 from the membrane
to the cytoplasmic perinuclear region (and similar to that of
zonula occludens-1 protein) has been demonstrated under the
influence of 50 AM lindane [101]. Moreover, lindane can
inhibit the phosphorylation of Cx43 induced by FSH and
TGFh-1 in rat ovarian granulose cells [102].
Next, the lipophilic agents should be considered. Among
lipophilic drugs, annihilative narcotics such as halothane or
isoflurane also can affect intercellular coupling. Incubation of
neonatal rat cardiomyocytes with 2 mM halothane resulted in a
90% reduction of initial junctional conductance within 15 s
without a change in single channel conductance [103].
Subsequently, it was found that halothane reduced the mean
open time while increasing the mean closed time [104].
Regarding the connexin isoforms, Cx40 channels seem to be
less sensitive than Cx43 channels or channels in cells co-
expressing Cx43 and Cx40 [104]. These effects may contribute
to the well known arrhythmogenic effects of halothane or
isoflurane.
Cardiac gap junction channels can be uncoupled using
micromolar concentrations of heptanol, octanol, myristoleic
acid, decaenoic acid or palmitoleic acid [105–107]. Most
commonly, this is explained by an incorporation of these drugs
into the lipid bilayer leading to impairment of the transcellular
gap junction channels. However, oleic acid reduces GJIC via
PKC-dependent Ser368 phosphorylation of Cx43 [43]. Simi-
larly, 18h-glycyrrhetinic acid reduces Cx43 immunopositivity
in the plasmamembrane [108]. The glycyrrhizic acid metabo-
lites 18-a-glycyrrhetinic acid, 18-h-glycyrrhetinic acid and
carbenoxolone have been shown to uncouple gap junction
channels in various models. Thus, several authors have used
18a-glycyrrhetinic acid as a gap junction inhibitor [109] in
concentrations of about 50 AM [110] or 18h-glycyrrhetinic acid
in a concentration of 5 AM [111]. Glycyrrhetinic acid has been
used in these studies for inhibition of intercellular communi-
cation in vascular tissue. It should be mentioned that these
drugs including carbenoxolone are not specific for gap
junctions. The effect of these compounds requires a longer
exposure time than the above-mentioned drugs.
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open probability of the channels by a conformational change
at the connexin–membrane lipid interface [112]. Many
investigators used heptanol which has been shown to inhibit
reversibly gj with a KD of 0.16 mmol/l. According to Ru¨disu¨li
and Weingart [15], the uncoupling effect of heptanol is fully
reversible within 2 min after washout in their experimental
system (The concentration–response curve revealed a steep S-
shaped relationship (Hill coefficient z =2.3) with a KD: 0.16
mmol/l). Oleic acid also closes gap junctions in neonatal rat
cardiomyocytes with an EC50 in the order of about 2 AM
[105,113]. Similarly, myristoleic acid and palmitoleic acid
lead to uncoupling with similar EC50 [105]. In whole heart
Langendorff preparations of rabbit hearts palmitoleic acid
exhibited a preferential impairment of transverse conduction
by the fatty acid and concomitant increase in dispersion with
an EC50 of 3.3 AM [114,107]. In that concentration range,
there was no effect on the transmembrane action potential of
isolated cells. The N-6 unsaturated fatty acid arachidonic acid
and precursor of eicosanoid metabolism also uncouples cells
with a KD of 4 Amol/l [115]. The concentration response curve
analysis revealed a KD of 4 Amol/l and a Hill coefficient of
0.75, and was partially reversible within 30 min. The recovery
could be accelerated by addition of fatty-acid free bovine
serum albumin (which binds fatty acids) to the bath solution.
Since the single channel conductance was not altered by
arachidonic acid in concentrations reaching 100 Amol/l, it was
concluded that arachidonic acid may reduce the open
probability of the channel. Interestingly, 100 Amol/l arachido-
nic acid did not affect non-junctional membrane currents. It
should be noted, that these lipophilic drugs are not very
specific for gap junctions and can inhibit other ion channels
as well.
Recently, it has been shown that 11,12-epoxyeicosatrienoic
acid also elicits an uncoupling effect which has been
demonstrated in endothelial cells. This effect was biphasic:
an initial improvement of interendothelial coupling was
followed by sustained uncoupling effect which seemed to
depend on activation of ERK1/2 [116]. This opens the
interesting view of an endogenous intracellular regulation of
intercellular communication.
Another eicosanoid reported to inhibit GJIC is thromboxane
A2. It was shown that a TXA2 mimetic reduced dye transfer
between human endothelial cells and led to internalization of
Cx43 [117]. This was associated with capillary formation and
thus might reflect a mechanism involved in angiogenesis.
The vascular GJIC can also be blocked using the cannabi-
noid receptor agonists D9-tetrahydrocannabinol (10–30 AM) or
the synthetic HU210 (10 AM) which both led to Cx43
phosphorylation in an ERK1/2-dependent manner associated
with reduction in electrical coupling and dye transfer within 15
min in cultured endothelial cells [118].
2.3. Drugs used for acute opening of gap junctions (Table 2)
In the following those drugs should be considered which
can improve GJIC within minutes. In early studies, it wasfound that intracellular cAMP in Purkinje fibres can enhance
coupling [119–121], while in others, there is no effect [48,55].
Since in Cx32 in hepatocytes the target for PKA-dependent
phosphorylation was identified as Ser-233 which is embedded
in a motive (Lys–Arg–Gly–Ser) known as a consensus
sequence for PKA or PKG, i.e., basic–basic-spacer-Ser and
since this sequence cannot be found in Cx43, one may argue
that Cx43 is not subject to direct phosphorylation by PKA. In
accordance with this, Kwak and Jongsma [55] investigated the
influence of 8-Br-cAMP, a direct activator of PKA, on dye
coupling and electrical coupling in pairs of neonatal rat cardiac
myocytes without detecting a change in coupling in response to
8-Br-cAMP. Thus, it might be that PKA activation may
enhance coupling in Cx40- and Cx45-coupled cells (such as
Purkinje fibres) but not in Cx43-coupled cells. This is
supported by van Rijen et al. [122] showing that human
Cx40 gap junction channels are modulated by cAMP in
SKHep1 cells stably transfected with human Cx40 cDNA.
The authors found an increase in macroscopic gap junctional
conductance by 46% accompanied by a mobility shift of Cx40
protein on Western blots after application of 1 mM 8-Br-cAMP.
Concomitantly, the single channel conductances changed:
while without cAMP single channel conductances of 30, 80
and 120 pS were observed, after cAMP unitary conductances
of 46 and 120 pS were detected. However, according to Christ
and Brink [58] (as established for Cx43-coupled cells), the
portion of a certain substate contributing to the macroscopic
conductance has also to be taken into account.
In venular endothelial cells 8-bromo-cAMP also enhanced
intercellular coupling [123], which might involve connexins
Cx43, Cx40 or Cx37. Since comparable results were obtained
in this study from cell lines expressing Cx43, the authors
assumed a Cx43-mediated effect. On the other hand, dye
transfer through Cx45 gap junction channels and electrical
coupling in Cx45-transfected SKHep1 cells is not influenced
by PKA activation [48], although an additional conductance
state was observed. In the same model transfectants, SKHep1/
Cx43 were investigated demonstrating that PKA did not
influence conductance of Cx43. However, the possibility that
PKA alters the open probability of the channels could not be
ruled out in this study since the effects were observed in the
presence of uncoupling agents. Additionally, it cannot be fully
excluded that in the transfected cell line proteins necessary for
the full and normal function of PKA are not expressed.
The role of PKA and cAMP in opening of gap junctions is
further supported by the finding that histamine in human tonsil
endothelial cells increases GJIC as a long-term effect acting via
H2 receptors [32], which are known to couple to Gs and
adenylylcyclase.
In addition, the bradycardiac agent tedisamil, which was
developed as an antiarrhythmic, has been shown to increase
gap junction conductance by 58% (0.1 AM) in cell pairs of
cardiomyopathic hamsters in dependence on PKA [124].
However, it should be noted that tedisamil has been reported
also to act on a number of other transmembrane ionic channels,
such as sodium and potassium channels. Thus, tedisamil does
not seem to be specific for gap junctions.
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antiarrhythmic peptides. First these peptides were isolated
from bovine atria in 1980 and increased synchronous beating
of embryonic chick heart cell clusters was seen [125]. The
structure was clarified as a hexapeptide (MW: 470; H2N-Gly-
Pro-4Hyp-Gly-Ala-Gly-COOH), which exhibited antiarrhyth-
mic properties in various classical arrhythmia models [126] (for
a detailed overview, see [127,128]). However, the mechanism
of action was unclear and after a paper stating that it did not
influence action potential parameters [129], the research on
these peptides seemed to cease. At that time, we were
interested in aspects of coupling, conduction and dispersion
of action potential duration [130] and started to investigate this
peptide. We initiated peptide synthesis, synthetised the natural
antiarrhythmic peptide in classical Merrifield synthesis using
Fmoc strategy and developed a number of chemically related
peptides. We also found improved synchronization of chick
embryonic cell clusters (unpublished observation) and could
demonstrate that the effect of AAPnat and related peptides
consists of an improvement of cellular coupling and an increase
in gap junctional conductance [131–134]. The lead structure,
the synthetic derivative AAP10 (H2N-Gly-Ala-Gly-Hyp-Pro-
Tyr-CONH2), possesses a semicyclic structure and can bind to
a membrane protein with a nanomolar KD [41,134–136]. Since
the AAP10 effect, consisting of enhancement of macroscopic
gap junction conductance and Cx43 phosphorylation, was
sensitive to GDP-hS (a G-protein inhibitor) and to PKC
inhibitors as well as to a PKCa-specific inhibitor (CGP54345),
it was concluded that AAP10 acts via a G-protein which
downstream activates protein kinase Ca leading (directly or
indirectly) to a phosphorylation of connexin43 resulting
directly or indirectly in an improvement of gap junction
conductance [41,132–134]. The putative receptor protein
which binds both AAP10 and AAPnat has been detected by
classical binding studies in the cell membrane [41,134,136]
and – taking the chemical studies of Grover and Dhein
[135,136] into account – is thought to build a cavity into which
the semicyclic drug can fit. From our experiments, we assumed
that the AAP10 effect is more pronounced in cells which are
partially uncoupled. It has been shown that AAP10 and
AAPnat did not exert other effects on cardiac tissue and did
not influence the cardiac action potential [129,131]. Thus,
according to our present knowledge, these peptides seem to be
specific for gap junctions.
The studies of Grover and Dhein [135,136] elucidated the
structure–activity relationships of antiarrhythmic peptides and
revealed a semicyclic horse shoe-like structure of AAP10
(H2N-Gly-Ala-Gly-4Hyp-Pro-Tyr-CONH2) which seemed to
be essential, since the cyclopeptide cAAP10RG, i.e.,
c(CF3(OH)C-GAGHypPY) could mimic all effects of
AAP10, while cyclopeptides with a longer or shorter bridge
were inactive, or peptides which cannot form this semicyclic
structure (e.g., GAGHypIY) (for more details on structure–
activity relationships, see [128,136]).
A group from Zealand developed a d-amino acid AAP10-
analogue ZP123 (H2N-Gly-D-Ala-Gly-D-4Hyp-D-Pro-D-Tyr-
Ac), which can be applied in vivo and was shown to be stablein plasma for several days and to possess a terminal half-life
time of 16 min in the rat [137]. Both AAP10 and ZP123 were
effective in antagonizing second degree atrioventricular block
induced by ouabain in mice [137]. Both drugs have been
shown to reduce dispersion of action potential duration in a
256-electrode mapping in isolated rabbit hearts [138], which
was not seen in the study by Kjolbye et al. [137] probably due
to the small number of electrodes (8 electrodes). As AAP10 or
AAPnat ZP123 also activates protein kinase C [138] and
slowly increases coupling [139] as was described for AAP10
[41].
Among the lipophilic drugs and fatty acids, the polyunsat-
urated N-3 fatty acid eicosapentaenoic acid (10 AM) has been
assumed to enhance or preserve gap junctional coupling in
human endothelial cells submitted to hypoxia/reoxygenation,
probably via antagonizing free radical effects [140]. Hypoxia/
reoxygenation reduced GJIC in these cells after 2 h of
reoxygenation, which could be inhibited by a 2 days pre-
treatment with 3 AM eicosapentaenoic acid [141]. Eicosapen-
taenoic acid in these experiments inhibited tyrosine phosphor-
ylation of Cx43 induced by hypoxia/reoxygenation, while
under normoxia, the drug had no effect on GJIC.
In the vasculature hyperpolarization and vasorelaxation can
be conducted along the vessel via interendothelial gap
junctions. In some species, hyperpolarization and vasorelaxa-
tion, conducted along the vessel via interendothelial gap
junctions [142,143], seem to be linked to NO/PGI2-indepen-
dent pathway coupled to the cytochrome P450 isoform CYP2C
and the generation of epoxyeicosatrienoic acids such as 11,12-
epoxyeicosatrienoic acid (11,12-EET) [116]. 11,12-EET (3
AM) had a biphasic effect on GJIC in human umbilical vein
endothelial cells as assessed by Lucifer Yellow dye transfer and
double cell voltage clamp. 11,12-EET transiently enhanced
GJIC within 1 min in a PKA-dependent manner, followed by a
prolonged uncoupling effect. Since EETs are potent intracel-
lular mediators and are involved in several signal transduction
cascades, these observations might be of general interest.
Moreover, in vascular smooth muscle improvement of GJIC by
5-hydroxytryptamine has been described [144].
Finally, a sulfur compound from garlic, diallyl-disulfide (1–
50 AM) time-dependently enhances GJIC via Cx43 in rat liver
epithelial cells [145].
2.4. Drugs used for regulation of connexin synthesis,
trafficking and degradation (Table 3)
In the last years, there is accumulating evidence that GJIC in
many cases is regulated via enhanced or depressed expression
of connexins, or by alteration of the gap junction density in the
membrane. A number of drugs which enhance connexin
expression or gap junction density in the membrane and GJIC
have been shown to exert anti-cancer effect and to reduce
tumor growth.
Thus, kaempferol, a flavonol and potential anti-cancer drug,
has been shown to enhance Cx43 expression and phosphory-
lation in colon cancer cells [146]. Kaempferol restored
differentiation in partially differentiated cancer cells but was
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Among the miscellaneous agents enhancing GJIC, the ethanol
extract of Indian medical herb psyllium has been described to
reduce tumor growth together with increases in GJIC in WB-
Ha-ras tumor cells [147,148]. This action seems to rely on h-
sitosterol contained in psyllium and an increase in Cx43
protein [147].
Carotenoids and retinoids also enhance Cx43 expression
and inhibit tumor growth by a G1 arrest, which may be related
to their anti-cancer efficacy (prevention) [149]. Thus, 24
h incubation of rat C6 glioma cells with 1–10 AM all-trans
retinoic acid increases GJIC, but does not affect Cx43mRNA
so that the authors assumed a posttranslational regulation [150].
On the other hand, 3–7 AM lycopene, a terpene serving as a
precursor of h-carotene, reported to reduce cancer risk, reduces
tumor cell growth and increases Cx43 protein and Cx43
mRNA in human oral cavity tumor KB-1 cells [151]. TAC-
101, an agonist at retinoic acid receptors, increased Cx43
expression without a change in phosphorylation and prevented
from inadequate Cx43 localisation in canine kidney cells
treated with the carcinogens KBrO3 and dimethylnitrosamine
[152]. Consequently, the impairment of GJIC under the
influence of the carcinogens was inhibited by TAC-101 in that
study. Similarly, the H2O-soluable carotenoid Na2-disuccinate
astaxanthine increases both Cx43 expression and gap junction
formation thereby improving GJIC [153]. However, although
h-carotene is known to enhance GJIC and Cx43 expression,
the clinical in vivo situation is more complex: in clinical trials,
additional dietary h-carotene increased lung cancer incidence.
High doses of the drug (50 mg/kg/day) also reduced GJIC in rat
liver. Interestingly, the oxidized form of h-carotene, which
might be generated in in vivo metabolism, inhibits GJIC at
concentrations of 5 AM in human A549 lung cancer cells [154],
a result which underlines the importance of the transfer of the
cell culture-based gap junction research to in vivo or isolated
organ disease models. Another example is indole-3-carbinal, a
natural anti-cancer agent, which, however, is converted to
indolo[3,2-b]carbazole in the stomach at acid pH. Incubation of
WB-F344 rat hepatocytes with 0.1–1 AM of this derivative for
8–12 h leads to reduced GJIC and loss of Cx32 expression
[155]. Indolo[3,2-b]carbazole is known as a tumor promoting
agent. The loss of GJIC has been linked to tumor progression
(see [156]) as was also recently shown for the reduction in
Cx26, Cx32 and GJIC in endometrial carcinoma cells (IK-ER1,
overexpressing the ERa-receptor) by 17h-estradiol acting via
ERa-receptors [157]. Several non-genotoxic carcinogens are
considered to impair the balance between cell growth and cell
death. This balance is often considered to be influenced by
GJIC, since growth regulatory signals can be exchanged
between the cells via gap junction channels and reduction in
GJIC, e.g., by loss of gap junction plaques, has been shown to
play a role in the cancer process. According to these
considerations, typical non-genotoxic carcinogens such as
Wy-14,643, methapyrilene, hexachlorobenzene and 2,3,7,8-
tetrachloro-dibenzo-p-dioxin (TCDD), chloroform and p-di-
chlorobenzene reduced the expression of Cx32 gap junction
plaques in liver and kidney of rats treated with these drugs for 3or 28 days [158]. Although this was not correlated with the
induction of cell proliferation, the authors nevertheless
concluded that this reduction in GJIC might be important in
the cancer process, if such a non-genotoxic carcinogen and this
reduction in GJIC occurs together with a proliferative stimulus
(or perhaps a terminal carcinogen). Among the epigenetic
tumor promoters, polychlorinated biphenyls (PCB) are effec-
tive in two stage cancer models. The non-planar PCB have
been shown to act as potent inhibitors of GJIC while the co-
planar PCB did not exert an effect on this parameter [159].
Phellinus linteus extract, derived from a mushroom consid-
ered a natural anticancer agent, has been shown to block the
p38 / ERK1/2 MAPK-mediated downregulation of Cx43–
GJIC and the hyper-phosphorylation of Cx43 in rat liver
epithelial cells [160]. Activation of p38 MAPK (by anisomy-
cin) was shown to result in downregulation of Cx32 in rat
hepatocytes [161].
An interesting additional aspect comes from a recent study
by Chen et al. [162] showing that in lung cancer cells (H2170
cells), the expression of Cx26 is reduced and that exposure to
the de-methylating agent 5-aza-deoxycytidine can lead to a
Cx26 re-expression, so that the authors concluded that the
reduction in Cx26 might be a consequence of Cx26 promotor
methylation. On the other, the anti-proliferative effects of
increased Cx43 expression should also be considered on the
background that the carboxy terminal of Cx43 (at least of this
connexin) suppresses growth, e.g., of N2A cells [163].
Besides cancer induction and anti-cancer treatment, phar-
macological interference with gap junction expression has been
shown to affect neurological function or disorders like seizure.
Thus, bicuculline methiodide (a GABA(A) receptor antagonist;
10 AM, 18 h) induces epilepsy-like discharges in cultured
hippocampal slices together with increased GJIC (indirectly
measured) and an increase in Cx43 and Cx32 protein and
mRNA levels as well as expression of the transcription factor
c-fos, while Cx26 and Cx36 were not affected. The epilepsy-
like discharges and GJIC in that model could be blocked by the
gap junction blocking agent carbenoxolone [164].
Moreover, amphetamine withdrawal (in vivo, rat model of
amphetamine addiction) results in reduced neuronal Cx36
expression in rat nucleus accumbens and prefrontal cortex,
which are areas known to be involved in the mechanism of
addiction [165].
Cortical astrocytes are coupled via Cx43. The Cx43 protein
and mRNA level can be reduced by epidermal growth factor
(EGF) in a MEK-dependent manner [166] (EGF is known to
induce hyperphosphorylation, ubiquitination and internaliza-
tion of Cx43 [167,168]). The level of Cx43 in these cells might
be important for the propagation of cell death during ischemia
as was elegantly shown by Contreras et al. [169] by inhibition
of GJIC in an astrocyte ischemia-model. Recently, it was also
demonstrated that endothelin can reduce expression of the
phosphorylated isoform of Cx43 and diminish GJIC in cultured
astrocytes [170].
Regarding the action of hormones, in the promoter region of
the Cx43 gene, a series of half-palindromic estrogen response
elements has been identified using a luciferase reporter [171].
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hormonal regulation of connexin expression. Thus, estradiol
enhances Cx26 together with a reduction in clusterin in rat
endometrium under in vivo conditions. The effect could be
inhibited by tamoxifen, raloxifen or diethylstilbestrol [172].
The effect on Cx26 is in contrast to that described by Saito et
al. [157]; however, the latter study was carried out in
endometrial cancer cells overexpressing ERa-receptors, so that
one might imagine that different signal transduction pathways
may be involved. Regarding Cx43, estradiol had no effect on
Cx43 in rat endometrium under in vivo conditions [172]. In
addition, 17h-estradiol (EC50: 400 nM) has been shown to
counteract the Ser-368-phosphorylation of Cx43 and reduction
in GJIC induced by metabolic inhibition in rat neonatal
cardiomyocytes [173]. Liu et al. [174] showed that in
ovariectomized female Wistar rats, Cx43 was significantly
downregulated in media and endothelium of mesenteric arteries
associated with a decreased EDHF response. Since this could
both be normalized by 17h-estradiol, estrogen seems to be
involved in the regulation of Cx43 in the vasculature (at least in
this model) in endothelial and myoendothelial gap junctions.
The functional interplay between the components of the
ovarian follicle is subject to hormonal regulation and is also
controlled by GJIC. The most abundant connexin in the follicle
is Cx43. FSH upregulates Cx43, while LH downregulates
Cx43 levels. This LH-induced downregulation is due to a
reduced rate of translation in a PKA and MAPK dependent
manner [175].
Finally, thyroid hormone receptors can bind to an element in
the Cx43 promotor identified at position 480 to 464 [176].
However, an increase in Cx43mRNA following thyroid
hormone treatment of Wistar rats was only seen in liver cells,
while in heart cells, there was no change in that study.
However, in neonatal rat cardiomyocytes, the thyroid hormone
T3 was shown to enhance Cx43 [177].
Another interesting aspect of chronic regulation of gap
junction expression involves the role of HMG-CoA-reductase
inhibitors, statins and low density lipoproteins (LDL) in the
formation and stabilization of atherosclerotic plaques. Thus,
after arterial lesions together with cholesterol-rich diet, an
upregulation of Cx43 has been observed in smooth muscle
cells in particular in the primary intimal layer, while it was
reduced in the media [178]. Cx43 was not found in the
macrophages in that study. In mice, a cholesterol-rich diet led
to downregulation of Cx37 and Cx40 in aortic endothelial cells.
Interestingly, the Cx37 decrease could be reversed by
simvastatin treatment, while the Cx40 downregulation could
not [179]. Moreover, in the vasculature of LDL-receptor-
deficient mice fed on a cholesterol-rich diet, the vascular
atheromas exhibited thicker fibrous caps (which would
decrease the risk of dissection) and less inflammatory cell
infiltration together with reduced Cx43 expression, if these
mice were treated with a HMG-CoA-reductase inhibitor
(pravastatin) [180]. In human vascular cells, it was shown that
HMG-CoA-reductase inhibitors (statins) can reduce Cx43
expression by a yet unknown mechanism [180]. On the other
hand, it was shown that nicotine can downregulate theexpression of Cx43 in human umbilical vein endothelial cells,
and that this effect can be attenuated by a number of statins
(fluvastatin, lovastatin, pravastatin, simvastatin) probably
independent from the mevalonate metabolism [181]. Thus,
among the various pleiotropic effects of statins, a modulatory
action on the expression of connexins has also to be
considered, which might contribute to the antiatherosclerotic
action of these drugs (probably with divergent actions in the
cell types involved (endothelium, neointimal cells, vascular
smooth muscle cells, etc.).
Several transcription factors have been identified to play a
role in the regulation of connexin expression. Regarding
transcriptional control of Cx43 and Cx40, the promotor regions
of Cx40 gene [182] and of Cx43 gene [183] contain an AP-1
Site. Additionally, a TATA box, an AP-2 site and an estrogen-
responsive element have been found [171] (see also above).
Moreover, the T-box transcription factor Tbx5 seems to be
involved in Cx40 regulation, since heterozygous Tbx5(del/+)
mice exhibited a marked downregulation of Cx40 [184].
The homeodomain-containing transcription factor Csx/
NKx2.5 (a member of the NK2-class homeodomain protein
and an early cardiogenic marker) may also be involved in the
regulation of Cx43 and Cx40. Mutation of the Csx/Nkx2.5
(I183P) in mice led to a marked downregulation of both
connexins [185]. The authors concluded that these connexins
may be direct or indirect downstream targets of Csx/NKx2.5.
Similar mutations have been detected in patients suffering from
congenital atrioventricular conduction defects. In support of
these findings, several consensus binding sites for Csx/NKx2.5
(TNAAGTG) [186] were found within the Cx40 and Cx43
promotors [182,187]. In addition, two Sp1/Sp3 binding sites
have been identified in the promotor of the rat Cx40 gene
contributing to the transcriptional activation of this gene in
cultured cells [188].
Since the gene structure of connexins is known, it is also
possible to inhibit gap junction expression specifically by the
delivery of antisense oligonucleotides. Thus, using (1994)5V-
GTCACCCATGTCTGGGCA-3V as Cx43 antisense and 5V-
GTCACCCATCTTGCCAAG-3V as Cx40 antisense in A7r5
cell (embryonic rat aorta smooth muscle cell line expressing
both Cx43 and Cx40) Moore and Burt could show, that 24
h treatment with one of the oligonucleotides (30 AM in cell
culture medium) could suppress the unitary conductances
specific for the target connexin [189]. This is, however, at
least at present only of experimental importance and not for
therapeutic use.
Regarding the regulation of connexin synthesis by classical
signal transduction pathways it has been shown that connexin
expression can be induced by the second messenger cAMP
[190]. Darrow and colleagues [190] found an upregulation of
Cx43 and Cx45 after 24 h treatment with dibutyryl cAMP in
cardiomyocytes. Accordingly, Salameh and colleagues
[191,192] showed an upregulation of Cx43 in neonatal
cardiomyocytes in response to forskolin, a direct activator of
adenylylcyclase. Thus, there is evidence that activation of the
adenylylcyclase/ cAMP /PKA pathway can enhance Cx43
expression. Because in the cardiovascular system this pathway
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anism might play an important role in the process of adaptation
of the heart to increased stress and higher heart rates.
Moreover, other factors stimulating adenylylcyclase as well
such as, e.g., prostaglandins might also have an effect on Cx43
expression. Besides in cardiomyocytes, cAMP also induces
synthesis of Cx43 in fibroblasts as was shown using the stable
analogue 8-Br-cAMP. Since this effect could be suppressed by
H89, it was concluded that the cAMP-effect on Cx43 synthesis
is mediated via PKA [193]. In that study, the role of serine 364
for the PKA-dependent effect was elucidated.
Gq/11-coupled receptor activation, typically leading to PKC
and MAPK activation (ERK1/2 or p38), also can upregulate
Cx43 synthesis as was shown in neonatal rat cardiomyocytes
by 24 h endothelin-1 exposure (10–1000 nM, each concen-
tration applied for 24 h) which lead to an increase in Cx43
expression (EC50:158T41 nM) and phosphorylation (EC50:
13T3 nM) while Cx40 remained unaffected [194]. The
increase in Cx43 was reflected by enhanced gap junctional
conductance in double cell patch clamp experiments after 24
h endothelin treatment after wash-out and in absence of
endothelin. The endothelin-effect was mediated via ETA-
receptors, since it could be antagonized by BQ123 (an ETA-
receptor antagonist), but not by BQ788 (an ETB-receptor
antagonist). Downstream, it was found that the enhanced Cx43
expression was dependent on ERK1/2 [194]. Similarly,
angiotensin-II, another agonist acting at Gq/11-coupled recep-
tors, also concentration-dependently can increase the expres-
sion of Cx43 [195]. In a subsequent detailed pharmacological
study 24 h exposure to angiotensin-II the treatment lead to
enhanced Cx43 protein levels (EC50: 57T10 nM) and
phosphorylation (EC50: 93T8 nM) and increased GJIC (10–
1000 nM, each concentration was applied for 24 h; electro-
physiological tests after thorough wash-out), while – as with
endothelin – there was no detectable change of Cx40 [194].
The angiotensin-II-induced Cx43 expression was mediated via
the AT1-receptor because of its sensitivity to losartan, an AT1
receptor antagonist [194]. Regarding the signal transduction
pathway, it was demonstrated that angiotensin activates both
ERK1/2 and p38 signal pathway [194]. Enhanced Cx43
expression via enhanced biosynthesis under the influence of
angiotensin-II was also observed in rat liver cells [196].
Interestingly, an antagonization of stretch-induced augmenta-
tion in Cx43 expression by the AT1-receptor antagonist losartan
has also been described supporting a role for angiotensin-II
mediated mechanisms in stretch-dependent regulation of
connexins [197].
Besides angiotensin-II, VEGF seems to play an important
role since Pimentel and colleagues [68] also found increased
Cx43 and conduction in cultures of neonatal rat cardiomyo-
cytes upon stretch in association with VEGF-secretion. This
stretch-induced enhancement of conduction could be antago-
nized by a VEGF antibody and by a TGF-h antibody indicating
that stretch might induce increase in Cx43 expression via a
TGF-h /VEGF pathway [68].
In cardiac remodelling processes, basic fibroblast growth
factor (bFGF) plays an important role. bFGF has been shownto induce Cx43 expression in cardiac fibroblasts within 6
h after administration associated with enhanced GJIC assessed
by scrape load technique [198]. Such regulation of intercel-
lular fibroblast communication might play a role in arrhyth-
mogenesis in cardiac fibrosis. Interestingly, in cardiomyocytes
bFGF exposure acutely (within 30 min) decreased gap
junctional coupling in a PKC(-dependent mechanism (see
above) [42]. Unfortunately, there are at present no data
available on the effects of chronic (24 h) bFGF stimulation
of cardiomyocytes.
In addition to the above-mentioned factors, cytokines may
also play a role in the chronic regulation of connexin
expression. In endocardial biopsies from heart transplant
recipients decreased Cx43 expression was found during acute
cellular rejection [199], indicating that cardiac allograft
rejection can lead to downregulation of Cx43. Among the
factors that could play a role in this pathophysiology, cytokines
and tumor necrosis factor a (TNFa) should be considered.
TNFa transduces its effects via TNFa-receptor associated
factors (TRAF1-6) and simultaneous activation of NF-kB,
JNK and p38 MAP-kinase. With regard to the TNFa-effect on
connexin expression, there are diverging results reported in the
literature: in bacterial lipopolysaccharide (LPS)-induced cardi-
ac inflammation in hearts in an in vivo rat model, Fernandez-
Cobo et al. [200] found a downregulation of Cx43–mRNA,
while in contrast, in lung and kidney, Cx43 was increased
following LPS-exposure [201] as was also found in liver [202].
In H9c2-cells (transfected with the Cx43-promotor), the Cx43
promotor activity could also be reduced by incubation with
lipopolysaccharides and to a similar extent with TNFa (2–500
ng/ml) [200]. In contrast, in cultured neonatal rat cardiomyo-
cytes, 24 h exposure to low concentrations of TNFa (10 U/ml)
increased Cx43 expression via p38 MAP-kinase [203,204].
This is in good accordance with the findings by McLaughlin
and colleagues [205] who demonstrated that TNFa can
stimulate MAPKAP kinase 3, which is a substrate of p38
MAP-kinase. In support of these data, Klein et al. [206] showed
that TNFa can indeed cause phosphorylation of p38 MAP-
kinase. Moreover, TNFa also increased Cx43 expression in
microglia cells if TNFa was applied together with interferon-
gamma, while it did not influence Cx43 if applied alone [207].
On the other hand, in endothelial cells, 0.5 nM TNFa did not
influence Cx43 expression but led to downregulation of Cx40
and Cx37 [208]. Thus, in different cell types, obviously
different signalling pathways connected to Cx43 regulation
are activated in response to TNFa-receptor stimulation (it
should be noted that the TNF receptor family comprises 18
receptors). It has further to be taken into account that higher
concentrations of TNFa also can induce apoptosis and cell
death, which might also influence gene transcription. Regarding
the septic shock model with LPS-exposure, many other factors
and complex hemodynamic changes may play a role as well.
Besides these receptor-mediated pathways, other agents
might affect connexin synthesis. Thus, ethanol reduces the
Cx43 biosynthesis in liver cells [196]. Together with reduced
GJIC, this was also seen in P19 cells using a concentration of
20 mM ethanol (approximately 0.1%) [209].
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assembly seems to be regulated by the interaction of Cx43
and zonula occludens ZO-1 protein [6]. Interestingly, it has
been found that c-Src, a tyrosine kinase which can phosphor-
ylate tyrosine residues of the Cx43 protein, leads to closure of
Cx43 gap junctional channels via disrupting the interaction of
ZO-1 and Cx43 involving tyrosine-phosphorylation of Cx43
[210]. This mechanism might play a role in the pathophys-
iology of heart failure, since in cells from cardiomyopathic
hamsters increased c-Src activity was found correlated with
increased tyrosine phosphorylation and reduced gap junctional
communication [211].
A number of substances and mediators have been shown to
interfere with the synthesis, formation, docking and degrada-
tion of the connexins. After synthesis, connexins are trans-
ported to the Golgi apparatus, oligomerized and thereafter
transported to the membrane [4]. It is possible to inhibit the
transport to the Golgi apparatus by brefeldin A as shown in a
very elegant study for Cx43 in cultured rat kidney cells [4].
Connexin can be trapped within the trans-Golgi network by the
metabolic inhibitor monensin [212]. Since connexins co-
localise with other proteins, regulation of these proteins is also
important to consider. In that regard, wnt-1 signalling has been
investigated. Wnt-1, a protooncogene encoding a secreted
developmental protein, was reported to result in increased
Cx43 transcription and accumulation of Cx43 co-localised with
h-catenin [213]. This was accompanied by enhanced coupling.
Since wnt-1 signalling regulates a variety of cells and
developmental processes, the influence of wnt-1 on Cx43
might be an interesting new aspect of Cx43 regulation.
Connexons dock to each other forming the complete gap
junction channel by interaction of their extracellular loops.
Antibodies raised against these extracellular domains have
been shown to inhibit gap junction assembly. From a
pharmacological point of view, it should be possible to interfere
with the docking process by adding peptide sequences
resembling only the extracellular loops as first described for
Cx32 [214] using them as a kind of competitive inhibitors. In
experiments using chick cardiomyocytes, the motifs QPG and
SHVR in extracellular loop 1 and SRPTEK in loop 2 were
identified [215]. In rabbit ear arteries, the peptides GAP27 and
GAP26 were used as inhibitors of GJIC formed by Cx43 and
Cx37 [216,217]. GAP26 has been reported to act primarily on
hemichannels [218] and may inhibit ATP release. A peptide-
analogoue of the second extracellular loop of Cx43, P180–195
(SLSAVYTCKRDPCPHQ; 500 AM) in A7r5 smooth muscle
cells inhibits coupling via Cx43 channels and a second peptide,
analogue to the second extracellular loop of Cx40, P177–192
(FLDTLHVCRRSPCPHP; 50 AM, higher concentrations could
not be used due to lower soluability) blocked coupling via
Cx40 channels [219]. Kwak and Jongsma [219] showed that 24
h treatment of the cultured cells was sufficient to suppress the
portion of intercellular coupling which could be ascribed to the
target connexins by suppression of the unitary conductance
specific for the target connexin. A peptide homologous to the
carboxy terminus was used as control peptide and did not affect
coupling. Another peptide often used for inhibition of dockingis also analogous to the extracellular loop of Cx43, called the
43GAP27 peptide (SRPTEKTIFII). In a concentration of 300
AM, it was shown to inhibit the endothelial component of
cannabinoid-induced relaxation in rabbit mesenteric artery
[110]. Moreover, acetylcholine-induced relaxation in rabbit
central ear artery could be antagonized by 300 AM GAP27.
However, the effect varied with the branching of the artery and
was more prominent in vessels of the second generation [220].
The last step in the life of gap junctions is the degradation of
connexins, which also can be modulated pharmacologically.
Connexins can be degraded either by the proteasomal pathway
or via the lysosomal pathway. Connexins can be degraded via
the lysosomal pathway after internalization (so called anular
gap junctions). Alternatively connexins can be degraded via the
ER-associated proteasome pathway (ER=endoplasmic reticu-
lum), which seems to be the prominent pathway for misfolded
or improperly oligomerized connexins [221]. Parts of the
degradation of Cx43 seem to be dependent on prior ubiquiti-
nylation of the protein. The lysosomal pathway can be
inhibited by protease inhibitors such as leupeptin or by
disruption of the pH gradient in the lysosome using chloro-
quine, primaquine or balifomycin A, leading to enhanced Cx43
presence in the cells [222]. The proteasome can be inhibited by
ALLN (acetyl–leucyl–leucyl–norleucinal), lactacystin, clas-
tolactacystin and epoxomicin [223]. These agents have been
widely used to study gap junction degradation, but there is no
therapeutic approach so far. Interestingly, Laing et al. [222]
showed that heat stress led to reduced Cx43 expression, which
could be prevented by lactacystin, ALLN and chloroquine.
These authors concluded that heat stress may mimic other
stress, such as ischemia, which also is known to reduce Cx43
expression.
2.5. Therapeutic perspectives and conclusions
There are a number of possible indications for of gap
junction affecting drugs including bone fracture, immune
system, heart disease, arrhythmia, atherosclerosis, learning,
seizure, regulation of secretion, female infertility, cancer,
inflammation and stem cell therapy. A number of drugs is
available affecting gap junctions on various levels. Problems
with these drugs still are specificity for a certain connexin or
organ and subcellular distribution/geometry, i.e., the question
whether a simple upregulation of a connexins leads to the
correct insertion and localisation of the newly formed gap
junctions.
Most studies addressing the pharmacology of gap junctions
are related to cell culture models. At present, there is a striking
lack of studies clearly demonstrating a beneficial effect of a gap
junction affecting drug in a disease model (in vivo or isolated
organ) or even in humans. This needs to be the next future step
in the chapter of pharmacology of gap junctions.
Seizure at a first glance is a result of abnormal excessive
synchronized electrical activity of large groups of neurons,
which is considered to be the consequence of disturbances of
the intracellular homeostasis of the cells, or of an imbalance
between excitatory and inhibitory activity. However, the
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order to involve larger cell groups thereby generating the
typical picture of a generalized seizure. This spreading has
been considered previously to be due to synaptical contacts
between the cells involved. However, in the past years, it was
found that cells of the nervous system (neurons and glia cells)
also exhibit gap junctions allowing the transfer of electrical
activity and establish a kind of ‘‘gap junction wiring’’ [224].
Thus, in rat central nervous system, Cx26, Cx30, Cx32, Cx36
and Cx43 has been detected. Oligodendrocytes express solely
Cx32, astrocytes Cx26, Cx30 and Cx43, ependymocytes only
Cx43, leptomeningeal cells Cx26 and Cx43, while neurons
express exclusively Cx36 in this species forming a highly
complex network [225]. From these findings, the hypothesis
can be formed that the generalization or spreading of seizure-
like activity might also involve gap junction coupling. In
support of this view, it was shown that seizure seems to be
sensitive to modulation of GJIC. Thus, seizure-like activity in
CA1 hippocampal region evoked by alkalization can be
suppressed by agents known to block gap junction (although
not specific) like carbenoxolone, sodium propionate and
octanol [226], indicating a possible anticonvulsant action of
gap junction blockers. In the future, brain-specific gap junction
modulator drugs would be needed, which possess pharmaco-
kinetic properties allowing the drug to pass the blood–brain
barrier.
In the heart, cardiac myocytes also form an electrical
network being in contact via gap junctions which are located
mainly at the cell poles, while at the lateral borders, there is no
or only minor expression of gap junctions. Together with the
elongated cell morphology, this forms the basis for the
anisotropic properties of the cardiac tissue with lower
resistance in longitudinal direction than in transverse (referred
to the fibre axis). This organization allows a regular spreading
of the action potential. The impulse normally is generated in
the sinus node (only very scarce expression of Cx43 at the
interface to the atrium), spreads over the atrium (Cx40>
Cx43>Cx45) to the atrioventricular node (sparse expression of
Cx40>>>Cx43>>Cx45), from where after delay, it passes to
the specific conduction system (Cx40>>>Cx43>>Cx45) and
finally reaches the ventricular myocardium (Cx43>>Cx45)
(for review, see [29,227,228]. Arrhythmia is a common and
serious problem in cardiovascular medicine involving supra-
ventricular and ventricular arrhythmia which may be tachyar-
rhythmic or bradyarrhythmic. Theoretically, gap junctions may
contribute to arrhythmia either by closure, e.g., during acute
myocardial infarction (due to a plethora of effects including
drop in pH, loss of ATP, Ca++ and Na+ overload and
accumulation of long chain acylcarnitines), or downregulation
(this, however, would probably means a very drastic down-
regulation of more than 90% (see [229])) leading to a
conduction deficit, or by disturbances in their distribution
within the tissue or within the cell (no longer confined to the
cell poles as was described for atrial fibrillation [230]), thereby
alterating the biophysics of the tissue. On the other hand, the
balance between current source and sink is import to allow
successful propagation (see [231]). According to these inves-tigations, propagation can fail if a small group of depolarizing
cells (‘‘source’’) is well coupled to a yet unpolarized large area
of cells (‘‘sink’’), since too much current is lost to a too large
area so that the current density is not high enough to allow
depolarization above the threshold resulting in conduction
failure [231]. Thus, loss of coupling, but on the other hand,
enhanced coupling both can – depending on the situation –
cause conduction failure. The involvement of gap junctions in
various forms of arrhythmia is still a matter of debate.
However, several models support the role of gap junction
uncoupling in arrhythmogenesis. Thus, atrioventricular con-
duction disturbances were shown in Cx40 knock-out mice
[232], while Cx43 knock-out is letal so that only heterozygous
Cx43+/ could be investigated which did not show ventricular
conduction failure [233], although the incidence of inducible
ventricular fibrillation was enhanced in one study [234] (for a
recent review on genetic models of connexin function in the
heart, see [228]). Pharmacological models, however, show
transverse conduction slowing and failure if gap junction
uncoupling drugs (heptanol, palmitoleic acid) are applied
[106,107]. Thus, regarding pathological electrical activation,
cardiac arrhythmia may be a target for gap junction modulating
drugs in some (but not all) forms of arrhythmia [127]. Thus, the
antiarrhythmic efficacy of antiarrhythmic peptides has been
shown in various models of acute arrhythmia (CaCl2, aconitine,
ischemia– reperfusion and ouabain) with some of these
peptides [131,137,139,235,236]. In addition, it was shown that
AAP10 enhances coupling and reduces dispersion (regional
inhomogeneity of action potential duration), which typically
predisposes for the occurrence of reentrant arrhythmia [131].
Moreover, Xing et al. [139] found that the AAP10-analogue
ZP123 (which also reduces dispersion [138]) prevented from
reentrant ventricular tachycardia at plasma concentrations
ranging from 1 to 69 nM in a dog model of reproducible
infarct-induced tachycardia.
In persisting heart disease, a special problem is the alteration
in the distribution of connexins with regional and subcellular
alterations and inhomogeneities (e.g., in atrial fibrillation
[230,237]). Moreover, the expression of connexins and the
ratio between Cx43 and Cx40 (and sometimes Cx45) can be
altered [238]. Such inhomogeneities in connexin distribution,
lateralization of connexins and alterations of the expression
level of a certain isoform may stabilize the arrhythmogenic
substrate. Thus, in these situations (e.g., chronic heart failure;
chronic phase of myocardial infarction; persisting atrial
fibrillation), a simple opening or closure of gap junctions
may be ineffective, and ways have to be detected to modulate
the biosynthesis and the correct localisation of the newly
formed connexins. However, it must also be stated clearly that
other factors also contribute to the arrhythmogenic substrate
such as age-dependent or atrial fibrillation-dependent increase
in fibrosis with mostly lateral accumulation of collagen and in
consequence transverse uncoupling [114,239].
In the cardiovascular field, hypertension and atherosclerosis
are among the most common problems in Western societies.
These diseases have a very complex pathophysiology which to
discuss is beyond the scope of this review. However, GJIC also
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vascular wall, Cx37, Cx40 and Cx43 are expressed in the
endothelial layer (intima), Cx43 and Cx45 in the media layer
(although Cx37 and Cx40 have also been described in certain
vessels [240]. The distribution of isoforms may vary depending
on the type of vessel and its position in the vascular tree [240].
There is communication within a layer (intima or media) along
the vessels’ axis and between the two layers [241,242].
Thus, GJIC plays also a role in the regulation of vascular
tone (see above) and has been shown to be involved in vascular
relaxation by the endothelium-derived hyperpolarizing factor
EDHF [109]. Rhythmic contractions of arteries (rabbit ear
arteries) also involve GJIC [216]. Moreover, it was demon-
strated that the up-stream vascular tone regulation is dependent
on GJIC [243]. A role for GJIC in the (complex) pathophys-
iology of hypertension is supported by the finding that Cx40
knock-out mice suffer from hypertension [244] and that Cx43
expression is upregulated in the smooth muscle aortic cells of
chronically hypertensive rats [240]. These observations indi-
cate that a modulation of GJIC may affect blood pressure,
although until today, there is no study demonstrating a clear
antihypertensive effect by gap junction modulation.
Regarding atherosclerosis, it was found that the expression
of connexins is altered within the atheroma [245–247].
According to these authors, monocytes invading the atheroma
mature to macrophages expressing Cx37, while smooth muscle
cells migrate to the intima exhibiting increased Cx43 expres-
sion in early atheroma. In this state, lipids start to accumulate in
the extracellular space and in the intimal smooth muscle cells.
Connexin expression in the endothelial cells and the media is
not altered. However, in advanced atheroma, a fibrous cap is
formed by intimal smooth muscle cells and extracellular matrix
and diseased endothelia cells. Cx43 in intimal smooth muscle
cells is downregulated at that stage and in the diseased
endothelial cells connexin expression is almost absent (cap),
while at the shoulder of the atheroma in that advanced stage the
endothelium expresses Cx43 [247]. One might image that the
lack of connexins in the cap region may destabilize the plaque
and make it more prone to dissection. Interestingly, it was
observed that statin therapy can upregulate Cx expression in
atherosclerosis [179,181] (and see above). This might be linked
to the observation that statins can stabilize atherosclerotic
plaques. In summary, GJIC plays a role in recruitment and
invasion of leukocytes in atherosclerosis as well as in
formation of the plaque [247], although this is probably not a
causal role, but may offer new possibilities to interfere with.
Thus, both hypertension and atherosclerosis might open
possibilities for gap junction modulators.
Cancer and anti-cancer therapy still is among the most
important problems in medicine. First of all, it is necessary to
understand the process of cancerogenesis, tumor initiation and
progression: the hallmarks of cancer according to Hanahan and
Weinberg [248], the self-sufficiency in growth signals, insen-
sivity to growth inhibitory signals, evasion of apoptosis,
limitedless replicative potential, sustained angiogenesis and
tissue invasion and metastasis. Thus, there is initiation of a
cell, promotion and thereafter invasive growth. It has beenhypothetized that at least in some cases, tissue stem cells and
early progenitor cells are the targets of the initiation event.
Since these cells are naturally immortal and become mortal
after differentiation, a cancerogenic process has to prevent
mortalization of these cells [249]. Three critical epigenetic
events contribute to cancerogenesis: inhibition of apoptosis,
disruption of communication resulting in a loss of growth
control by the neighboring cells [250] and activation of a
mitogenic pathway [159]. It was Loewenstein as early as 1966
[251] formulating that GJIC is associated with growth control
and differentiation in normal cells and – in consequence – that
cancer cell loose their ability to communicate with the
neighboring cells via gap junctions. There is a large body of
evidence that GJIC is involved in cancer promotion (by
epigenetic cancerogens/promoters or other factors) [for review,
see [252]. Thus, an important therapeutic indication for gap
junction modulating drugs might be the modulation of GJIC in
particular by affecting the biosynthesis of connexins in anti-
cancer therapy [156]. In principle, enhanced GJIC can restore
growth control of a cell by its neighbors and the balance
between cell growth and cell death. Most tumor cells show
reduced (or no) connexin expression and, thus, re-expression of
connexins and restoration of functional communication be-
tween the cells has been shown to reduce tumor cell growth.
The anti-growth potential of carotenoids has been related to
their ability to enhance GJIC [150–155] and a number of
studies, which not all can be cited here, indicate a tumor-
suppressing role for drugs which enhance GJIC [150–160].
However, to evaluate the clinical importance of these data (see
[156] and above), it is necessary to test this therapeutic
approach in in vivo cancer models.
In particular, after metastasation, this therapeutic approach
might reach its limits since it only works if the connexins of the
tumor cell (being influenced by the treatment) and those of the
surrounding cells (recipient tissue, where the metastasis is) can
form functional gap junction channels, which is not possible
between all connexin-isoforms.
In conclusion, modulation of GJIC may open interesting
new therapeutic approaches for a large number of diseases
since intercellular communication in many organs plays a vital
role. However, in many respects, we have not completely
understood the complex networking and its long-term regula-
tion. This again underlines the need for in vivo and organ-
based models to evaluate the possibilities of pharmacological
approaches towards an acute or chronic modulation of gap
junctions. Moreover, the development of connexin- or organ
specific gap junction modulator drugs is a challenging task for
pharmacologists.
Note: 2066 papers have been published so far concerning
somehow the pharmacology of gap junctions and have been
checked for this article. The present review here is focussed
(not limited) on the developments for the last 5 years. Due to
space limitations we were not able to include the complete list
of all references regarding this area and tried to limit this list to
those which are directly concerned with pharmacology. Several
important articles may have not been included due to the space
limitations and we ask for the understanding of the reader.
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